Literature DB >> 24244017

Optineurin insufficiency impairs IRF3 but not NF-κB activation in immune cells.

Ivana Munitic1, Maria Letizia Giardino Torchia, Netra Pal Meena, Guozhi Zhu, Caiyi C Li, Jonathan D Ashwell.   

Abstract

Optineurin is a widely expressed polyubiquitin-binding protein that has been implicated in regulating cell signaling via its NF-κB essential modulator-homologous C-terminal ubiquitin (Ub)-binding region. Its functions are controversial, with in vitro studies finding that optineurin suppressed TNF-mediated NF-κB activation and virus-induced activation of IFN regulatory factor 3 (IRF3), whereas bone marrow-derived macrophages (BMDMs) from mice carrying an optineurin Ub-binding point mutation had normal TLR-mediated NF-κB activation and diminished IRF3 activation. We have generated a mouse model in which the entire Ub-binding C-terminal region is deleted (Optn(470T)). Akin to C-terminal optineurin mutations found in patients with certain neurodegenerative diseases, Optn(470T) was expressed at substantially lower levels than the native protein, allowing assessment not only of the lack of Ub binding, but also of protein insufficiency. Embryonic lethality with incomplete penetrance was observed for 129 × C57BL/6 Optn(470T/470T) mice, but after further backcrossing to C57BL/6, offspring viability was restored. Moreover, the mice that survived were indistinguishable from wild type littermates and had normal immune cell distributions. Activation of NF-κB in Optn(470T) BMDM and BM-derived dendritic cells with TNF or via TLR4, T cells via the TCR, and B cells with LPS or anti-CD40 was normal. In contrast, optineurin and/or its Ub-binding function was necessary for optimal TANK binding kinase 1 and IRF3 activation, and both Optn(470T) BMDMs and bone marrow-derived dendritic cells had diminished IFN-β production upon LPS stimulation. Importantly, Optn(470T) mice produced less IFN-β upon LPS challenge. Therefore, endogenous optineurin is dispensable for NF-κB activation but necessary for optimal IRF3 activation in immune cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24244017      PMCID: PMC3886234          DOI: 10.4049/jimmunol.1301696

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  69 in total

Review 1.  Roles of the NF-kappaB pathway in lymphocyte development and function.

Authors:  Steve Gerondakis; Ulrich Siebenlist
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-23       Impact factor: 10.005

2.  The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways.

Authors:  Tiejun Zhao; Long Yang; Qiang Sun; Meztli Arguello; Dean W Ballard; John Hiscott; Rongtuan Lin
Journal:  Nat Immunol       Date:  2007-04-29       Impact factor: 25.606

3.  Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription.

Authors:  M Bonnard; C Mirtsos; S Suzuki; K Graham; J Huang; M Ng; A Itié; A Wakeham; A Shahinian; W J Henzel; A J Elia; W Shillinglaw; T W Mak; Z Cao; W C Yeh
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

Review 4.  NF-κB in immunobiology.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

5.  Derivation of embryonic stem cell lines.

Authors:  S J Abbondanzo; I Gadi; C L Stewart
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

6.  Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.

Authors:  Q Li; D Van Antwerp; F Mercurio; K F Lee; I M Verma
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

7.  Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation.

Authors:  Dietrich B Conze; Chuan-Jin Wu; James A Thomas; Allison Landstrom; Jonathan D Ashwell
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

8.  Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP.

Authors:  Guozhi Zhu; Chuan-Jin Wu; Yongge Zhao; Jonathan D Ashwell
Journal:  Curr Biol       Date:  2007-08-21       Impact factor: 10.834

9.  Optineurin suppression causes neuronal cell death via NF-κB pathway.

Authors:  Mayumi Akizuki; Hirofumi Yamashita; Kengo Uemura; Hirofumi Maruyama; Hideshi Kawakami; Hidefumi Ito; Ryosuke Takahashi
Journal:  J Neurochem       Date:  2013-06-17       Impact factor: 5.372

10.  Glial cells in amyotrophic lateral sclerosis.

Authors:  Jurate Lasiene; Koji Yamanaka
Journal:  Neurol Res Int       Date:  2011-06-07
View more
  33 in total

1.  Inducible turnover of optineurin regulates T cell activation.

Authors:  Angela Montecalvo; Simon C Watkins; Jordan Orange; Lawrence P Kane
Journal:  Mol Immunol       Date:  2017-02-11       Impact factor: 4.407

2.  The TBK1-binding domain of optineurin promotes type I interferon responses.

Authors:  Netra Pal Meena; Guozhi Zhu; Paul R Mittelstadt; Maria Letizia Giardino Torchia; Marie Pourcelot; Damien Arnoult; Jonathan D Ashwell; Ivana Munitic
Journal:  FEBS Lett       Date:  2016-05-04       Impact factor: 4.124

Review 3.  Modelling amyotrophic lateral sclerosis in rodents.

Authors:  Tiffany W Todd; Leonard Petrucelli
Journal:  Nat Rev Neurosci       Date:  2022-03-08       Impact factor: 34.870

Review 4.  Autophagy Dysfunction in ALS: from Transport to Protein Degradation.

Authors:  Marta Cozzi; Veronica Ferrari
Journal:  J Mol Neurosci       Date:  2022-06-16       Impact factor: 2.866

5.  Optineurin Deficiency and Insufficiency Lead to Higher Microglial TDP-43 Protein Levels.

Authors:  Nikolina Prtenjaca; Matea Rob; Muhammad S Alam; Andrea Markovinovic; Cristiana Stuani; Emanuele Buratti; Ivana Munitic
Journal:  Int J Mol Sci       Date:  2022-06-19       Impact factor: 6.208

6.  RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.

Authors:  Yasushi Ito; Dimitry Ofengeim; Ayaz Najafov; Sudeshna Das; Shahram Saberi; Ying Li; Junichi Hitomi; Hong Zhu; Hongbo Chen; Lior Mayo; Jiefei Geng; Palak Amin; Judy Park DeWitt; Adnan Kasim Mookhtiar; Marcus Florez; Amanda Tomie Ouchida; Jian-bing Fan; Manolis Pasparakis; Michelle A Kelliher; John Ravits; Junying Yuan
Journal:  Science       Date:  2016-08-05       Impact factor: 47.728

7.  Inhibitory feedback control of NF-κB signalling in health and disease.

Authors:  Jack A Prescott; Jennifer P Mitchell; Simon J Cook
Journal:  Biochem J       Date:  2021-07-16       Impact factor: 3.857

8.  Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease.

Authors:  Henry C Tseng; Ching-Chang Ko; Jennifer Martinez; Sing-Wai Wong; Bo-Wen Huang; Xiangxiang Hu; Eui Ho Kim; Joseph P Kolb; Ricardo J Padilla; Peng Xue; Lufei Wang; Thomas H Oguin; Patricia A Miguez
Journal:  Cell Death Differ       Date:  2019-05-10       Impact factor: 15.828

Review 9.  Immune diseases caused by mutations in kinases and components of the ubiquitin system.

Authors:  Philip Cohen
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

Review 10.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.